广济药业(000952) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 133,271,899.34, a decrease of 24.42% compared to CNY 176,325,538.59 in the same period last year[4] - Net profit attributable to shareholders was CNY 8,356,171.56, down 39.62% from CNY 13,838,265.84 year-on-year[4] - Total operating revenue for Q1 2022 was CNY 133,271,899.34, a decrease of 24.4% compared to CNY 176,325,538.59 in the same period last year[22] - Net profit for Q1 2022 was CNY 7,655,581.24, a decline of 40.5% from CNY 12,935,440.72 in Q1 2021[24] - The company's operating profit for Q1 2022 was CNY 8,728,468.35, down 51.2% from CNY 17,897,295.19 in the previous year[23] - The company's basic earnings per share decreased by 56.29% to CNY 0.0243 from CNY 0.0556 in the same period last year[4] - Earnings per share for Q1 2022 were CNY 0.0243, compared to CNY 0.0556 in Q1 2021[24] Cash Flow - The net cash flow from operating activities was negative at CNY -329,051.98, a decline of 101.15% compared to CNY 28,496,950.04 in the previous year[4] - Cash flow from operating activities in Q1 2022 was CNY -329,051.98, a significant decrease from CNY 28,496,950.04 in Q1 2021[26] - The total cash inflow from operating activities was CNY 167,905,381.54, compared to CNY 171,384,340.33 in the same period last year[26] - The net cash flow from investment activities was -46,697,286.75, compared to -23,944,091.49 in the previous year, indicating a significant increase in cash outflow[27] - The total cash inflow from financing activities was 334,443,480.00, up from 102,651,520.00 in the same period last year, reflecting a strong financing effort[27] - The net cash flow from financing activities was 162,240,812.11, compared to -28,468,667.35 in the previous year, showing a positive turnaround[27] - The cash and cash equivalents increased by 115,115,827.44, contrasting with a decrease of -23,814,552.10 in the previous year[27] - The total cash and cash equivalents at the end of the period amounted to 318,188,097.11, compared to 265,723,641.72 at the end of the previous year[27] - The company received cash from borrowings amounting to 275,000,000.00, compared to 102,651,520.00 in the previous year, indicating increased leverage[27] Assets and Liabilities - Total assets increased by 13.06% to CNY 2,316,525,859.76 from CNY 2,048,896,426.54 at the end of the previous year[4] - The total liabilities as of March 31, 2022, were CNY 1,047,438,850.65, compared to CNY 739,955,538.71 at the beginning of the year, reflecting an increase of approximately 41.6%[19] - Total liabilities as of Q1 2022 amounted to CNY 858,073,922.87, an increase from CNY 598,092,478.58 in the previous year[23] - The company's long-term borrowings rose dramatically by 521.04% to CNY 213,950,000.00, reflecting increased financing needs for operations[8] - The company's cash and cash equivalents increased to CNY 405,484,067.73 from CNY 293,332,160.43, representing a growth of about 38.2%[18] - Accounts receivable rose to CNY 193,938,139.72 from CNY 182,981,957.15, indicating an increase of approximately 6.4%[18] - The company's long-term equity investments increased to CNY 38,738,693.52 from CNY 32,513,867.21, showing a growth of about 19.1%[19] Inventory and Expenses - The company’s inventory increased by 32.49% to CNY 218,384,674.56, attributed to higher procurement of pharmaceutical distribution and trading[8] - Total operating costs for Q1 2022 were CNY 134,378,996.03, down 15.5% from CNY 158,967,357.47 in Q1 2021[23] - The company reported a significant increase in financial expenses by 59.45% to CNY 4,666,459.58 due to increased borrowing[10] - The company reported a decrease in research and development expenses to CNY 9,185,119.75 from CNY 7,506,265.22 in the previous year, indicating a 22.4% increase[23] - The company spent 46,998,496.47 on the acquisition of fixed assets, intangible assets, and other long-term assets, compared to 24,183,491.49 in the previous year, indicating increased capital expenditure[27] Strategic Initiatives - The company plans to implement a mixed reform strategy by introducing a research and development team to enhance its capabilities in drug formulation and production[16] - Hubei Guangji Pharmaceutical has established a subsidiary, Hubei Guangji Pharmaceutical Technology Co., Ltd., to strengthen its R&D efforts, which was registered in March 2022[16] - The company has approved a restricted stock incentive plan, granting 8.649 million shares at a price of CNY 3.52 per share to 118 eligible participants[14] Reporting and Audit - The company did not undergo an audit for the first quarter report[28] - The report was published by the board of directors on April 27, 2022[29]